These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26864802)

  • 21. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
    Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
    J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
    Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
    Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of HCV testing approaches in low and middle income countries.
    Morgan JR; Servidone M; Easterbrook P; Linas BP
    BMC Infect Dis; 2017 Nov; 17(Suppl 1):697. PubMed ID: 29143681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
    Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
    Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
    Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M
    Hepatology; 2013 Nov; 58(5):1598-609. PubMed ID: 23553643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T
    PLoS One; 2021; 16(2):e0245896. PubMed ID: 33571196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    Heffernan A; Ma Y; Nayagam S; Chan P; Chen Z; Cooke GS; Guo Y; Liu C; Thursz M; Zhang W; Zhang X; Zhang X; Jia M; Hallett TB
    PLoS One; 2021; 16(1):e0245288. PubMed ID: 33439903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom.
    Williams J; Vickerman P; Douthwaite S; Nebbia G; Hunter L; Wong T; Ruf M; Miners A
    Value Health; 2020 Aug; 23(8):1003-1011. PubMed ID: 32828211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
    Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
    Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing for hepatitis C virus infection in UK prisons: What actually happens?
    Jack K; Thomson BJ; Irving WL
    J Viral Hepat; 2019 Jun; 26(6):644-654. PubMed ID: 30702194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
    Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
    J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
    Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
    Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis.
    Duchesne L; Dussault C; Godin A; Maheu-Giroux M; Kronfli N
    Int J Drug Policy; 2021 Oct; 96():103345. PubMed ID: 34176704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
    Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing.
    Perrett SE; Plimmer A; Shankar AG; Craine N
    J Public Health (Oxf); 2020 May; 42(2):423-428. PubMed ID: 32090269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.